Bob Dempsey serves as Chief Operating Officer of Meibum Scientific and brings decades of executive leadership experience in ophthalmology, biotechnology, and global pharmaceutical commercialization.
Mr. Dempsey is currently Interim CEO of Ashvattha Therapeutics, where he oversees the development of Migaldendranib (MGB), a novel targeted nanomedicine for diabetic macular edema and neovascular age related macular degeneration. Previously, he served as CEO and President of AsclepiX Therapeutics and as CEO of TearClear, where he drove commercial strategy, regulatory engagement, and a successful Series B financing.
Earlier in his career, Mr. Dempsey served as Group Vice President and Head of Global Ophthalmology at Shire (now Takeda). In that role, he led the global launch of Xiidra®, including a transaction with more than $1 billion in upfront value and a subsequent $1.7 billion acquisition by Bausch & Lomb. He also oversaw multiple strategic acquisitions that expanded Shire’s ophthalmology pipeline.
Mr. Dempsey serves on multiple boards including iVeena Delivery Systems, TearSolutions, Azalea Vision, and Signal 12, and is a Co-Founder and Board Member of the Holland Foundation for Sight Restoration.